Jazz Pharmaceuticals PLC $JAZZ Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.3% during the 1st quarter, Holdings Channel.com reports. The firm owned 535,062 shares of the specialty pharmaceutical company’s stock after selling 12,681 shares during the period. The Manufacturers Life Insurance Company’s holdings in Jazz Pharmaceuticals were worth $101,153,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the business. Cardinal Capital Management lifted its holdings in shares of Jazz Pharmaceuticals by 0.5% during the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after purchasing an additional 66 shares during the last quarter. Bessemer Group Inc. grew its stake in Jazz Pharmaceuticals by 0.3% during the 1st quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock worth $4,228,000 after buying an additional 73 shares during the last quarter. UMB Bank n.a. grew its stake in Jazz Pharmaceuticals by 12.6% during the 4th quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 81 shares during the last quarter. Pinnacle Associates Ltd. increased its position in Jazz Pharmaceuticals by 0.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after buying an additional 83 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC increased its position in Jazz Pharmaceuticals by 4.4% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock valued at $377,000 after buying an additional 85 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of a number of research analyst reports. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $188.00 to $307.00 in a research note on Tuesday, May 19th. Raymond James Financial restated an “outperform” rating and set a $239.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Sanford C. Bernstein restated a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. TD Cowen increased their price objective on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Needham & Company LLC lifted their target price on shares of Jazz Pharmaceuticals from $255.00 to $282.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $259.06.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $256.92 on Wednesday. The firm has a market capitalization of $16.14 billion, a price-to-earnings ratio of -12,839.58, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The business has a fifty day moving average of $238.28 and a 200 day moving average of $204.68. Jazz Pharmaceuticals PLC has a 1 year low of $105.00 and a 1 year high of $261.30.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. As a group, research analysts expect that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Mark Douglas Smith sold 1,157 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $230.55, for a total value of $266,746.35. Following the sale, the director owned 9,680 shares in the company, valued at $2,231,724. This represents a 10.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the completion of the transaction, the director owned 366,682 shares in the company, valued at approximately $88,176,020.54. This trade represents a 1.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 13,098 shares of company stock valued at $3,131,906. 4.10% of the stock is owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.